Brighter News For Varlitinib As Results In Tough Cancer Type Encourage ASLAN
Executive Summary
Following a major setback in another indication earlier this year, ASLAN’s lead asset is now seen as a potential new option for second-line use in biliary tract cancer following promising new data from a Chinese trial.
You may also be interested in...
ASLAN Falls As TreeTopp BTC Study Fails
ASLAN’s pivotal Phase II TreeTopp study of varlitinib in biliary tract cancer missed its co-primary endpoints of progression-free survival and overall response rate.
ASLAN, Sosei Pipeline Assets Hit By Development Delays
Two Asia-based companies disclose delays to important clinical pipeline assets, one in oncology driven by apparent ethnic differences in response to prior therapy and the other a CNS molecule hit by an unexpected toxicity finding in an animal study.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.